Show simple item record

dc.contributor.authorLim, Hoong Sern
dc.contributor.authorLease, Erika D D
dc.date.accessioned2023-09-26T11:13:04Z
dc.date.available2023-09-26T11:13:04Z
dc.date.issued2023-08-21
dc.identifier.citationLim HS, Lease EDD. Donor lung allocation scheme: how can we measure success? Thorax. 2023 Aug 21:thorax-2023-220643. doi: 10.1136/thorax-2023-220643. Epub ahead of print. PMID: 37604692.en_US
dc.identifier.eissn1468-3296
dc.identifier.doi10.1136/thorax-2023-220643
dc.identifier.pmid37604692
dc.identifier.urihttp://hdl.handle.net/20.500.14200/2303
dc.description.abstractThe National Health Service Blood and Transplant Cardiothoracic Advisory Group, in line with the principles of priority to the sickest and equal access to opportunities to benefit from transplantation, revised the UK Lung Allocation Scheme (UKLAS) from a geography-based to a clinical urgency-based scheme. The primary aim was to prioritise the sickest registered lung transplant candidates, providing access to the national donor lung pool, irrespective of geographical zones. Two criteria-based urgent tiers were adopted in the 2017 UKLAS: (1) the super-urgent lung allocation scheme (SULAS) for patients on extracorporeal membrane oxygenation support and (2) the urgent lung allocation scheme (ULAS) for patients with deterioration in disease-specific physiological parameters.en_US
dc.language.isoenen_US
dc.publisherBMJ Publishing Groupen_US
dc.relation.urlhttps://thorax.bmj.com/content/early/2023/08/20/thorax-2023-220643en_US
dc.subjectRespiratory medicineen_US
dc.subjectSurgeryen_US
dc.subjectCardiologyen_US
dc.titleDonor lung allocation scheme: how can we measure success?en_US
dc.typeArticle
dc.source.journaltitleThorax
dc.source.countryEngland
rioxxterms.versionNAen_US
dc.contributor.trustauthorSern, Lim
dc.contributor.departmentCardiologyen_US
dc.contributor.roleMedical and Dentalen_US
oa.grant.openaccessnaen_US


This item appears in the following Collection(s)

Show simple item record